DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
u•••••• B••
Drug Discovery & Developmentgroup grade Bon a schedule nowsponsor unattributed
Also written as: 1; 1/31/2019; 2019; 31; Equity
Principal held
at least $27.5M
sum of BDC pieces, a lower bound
Fair value
$30.1M
103c on cost, debt pieces
Unfunded
n/a
commitments not yet drawn
BDC lenders
1
1 on the latest quarter
Facilities
1
1 equity pieces beside them
Next maturity
Oct 1, 2030
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Jun 30, 2026
Events
3
dated, non-routine
Capital structure as the BDCs see it
latest quarter end Jun 30, 2026
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien | at least $27.5M | 103c | S+245 bp | Oct 1, 2030 | 1 |
Equity pieces beside the debt: equity ($1.6M fair value, 1 BDC)
Lenders
every BDC piece at the latest quarter end
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| H••••••• C••••••• I••• | term loan first lien S••••• S••••••, O•••••• 2030, P•••• + 2.45%, F•••• rate 9.45%, 5.50% E••• Fee | $27.5M | $28.5M 103c | S+245 bp |
| H••••••• C••••••• I••• | equity equity C••••• S•••• | n/a | $1.6M 142c |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Jun 30, 2026 | 1 | $27.5M | $28.5M | 103c | 0 |
| Mar 31, 2026 | 1 | $27.5M | $28.0M | 102c | 0 |
| Dec 31, 2025 | 1 | $27.5M | $28.1M | 102c | 0 |
| Sep 30, 2025 | 1 | $27.5M | $28.6M | 100c | 0 |
| Jun 30, 2025 | 1 | $35.0M | $37.1M | 102c | 0 |
| Mar 31, 2025 | 1 | $35.0M | $37.1M | 102c | 0 |
| Dec 31, 2024 | 1 | $35.0M | $37.1M | 103c | 0 |
| Sep 30, 2024 | 1 | $35.0M | $37.1M | 103c | 0 |
| Jun 30, 2024 | 1 | $70.0M | $74.1M | 103c | 0 |
| Mar 31, 2024 | 1 | $70.0M | $73.4M | 103c | 0 |
| Dec 31, 2023 | 1 | $210M | $220M | 103c | 0 |
| Sep 30, 2023 | 1 | $70.0M | $73.2M | 103c | 0 |
| Jun 30, 2023 | 1 | $70.0M | $72.1M | 102c | 0 |
| Mar 31, 2023 | 1 | $70.0M | $74.0M | 102c | 0 |
| Dec 31, 2022 | 1 | $70.0M | $73.0M | 101c | 0 |
What changed
- Maturity extended (observed)Sep 30, 2025
- Spread changed (observed)Sep 30, 2025
- Maturity extended (observed)Sep 30, 2025
- Maturity shortened (observed)Mar 31, 2024
- Maturity extended (observed)Dec 31, 2023
- Maturity extended (observed)Dec 31, 2023
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- UNIQURE #NLderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 1 BDCderived
- Industry
- Drug Discovery & Developmentreportedas one filer wrote it